Sign in
CompletedPhase 1

Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors

Key facts

Who runs it
Suzhou Zanrong Pharma Limited
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
61 people enrolled
Started
15 Oct 2020
Ended
16 Apr 2025
Type of study
Interventional, 11 groups
Treatments tested
  • ZN-A-1041 50mg BID
  • ZN-A-1041 100mg BID
  • ZN-A-1041 200mg BID
  • ZN-A-1041 400mg BID
  • ZN-A-1041 600mg BID
  • ZN-A-1041 800mg BID
  • ZN-A-1041 1000mg BID
  • ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
  • ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
  • ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
  • ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle
Record updated
11 August 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • ECOG performance status of 0 to 1 2. HER2-positive is defined as Immunohistochemistry (IHC) (++) and Fluorescence In Situ Hybridization (FISH) positive, or IHC (+++)
  • Phase 1a study will enroll patients with unresectable or metastatic HER2-positive advanced solid tumor; Phase 1b study will enroll patients with unresectable locally-advanced or metastatic HER2+ breast cancer
  • For patients who have no brain metastases, the following criteria should be met:
  • Patients should be relapsed or refractory to existing therapy(ies) or have been intolerant of such therapies
  • Have at least one extracranial measurable lesion by RECIST v1. 1 ii. For patients with brain metastasis, the following criteria should be met:
  • Have received prior treatment or patient declined the above treatment; 2) Patients with HER2-positive gastric cancer must have previously received Trastuzumab 3) Do not require immediate local treatment during the trial period, and meet either of the following two criteria:
  • For patients who have received previous local treatment (surgery, whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS)) for brain metastases, stable or progression of intracranial lesions is required. Interval from prior local therapy could be 3 weeks from WBRT and 2 weeks from SRS
  • Symptomatic or not, patient has not received previous local treatment (surgery or radiotherapy) for brain metastases as long as no local therapy is needed during the trial period
  • In Phase 1a, for patients who have received previous tyrosine kinase inhibitor (TKI) treatment, chemotherapy, antibody, or antibody-drug conjugate (ADC), the interval between the last treatment and the first administration of the study drug in this trial should be at least 2 weeks. In Phase 1b, for patients who have received previous trastuzumab or other antibodies, the interval between the last treatment and the first administration of the study drug in this trial should be at least 3 weeks
  • Phase 1c study will enroll patients with unresectable locally-advanced or metastatic HER2+ breast cancer with brain metastases
  • For patients with brain metastasis, patients do not require immediate local treatment during the trial period, and meet either of the following two criteria:
  • For patients who have received previous local treatment (surgery, whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS)) for brain metastases, stable or progression of intracranial lesions is required. Interval from prior local therapy could be 3 weeks from WBRT, 2 weeks from SRS and 4 weeks from surgery
  • Symptomatic or not, patient has not received previous local treatment (surgery or radiotherapy) for brain metastases as long as no local therapy is needed during the trial period
  • Have at least one measurable lesion and is suitable for accurate repeated assessable by RECIST 1.1, and the patient has an imaging-diagnosable intracranial lesion
  • Patients should not include suspected or confirmed meningeal metastases
  • The patient had no disease progression with previous 12 weeks' capecitabine therapy
  • No capecitabine therapy within 6 months
  • Patient should not previously treat with a tyrosine kinase inhibitor (TKI). Previous treatment with trastuzumab or other antibodies should be at least 3 weeks apart from the first treatment

Who cannot take part

  • Subjects who have participated in any clinical study or received any clinical study drug within 4 weeks prior to the first administration
  • Previous cumulative dose of doxorubicin exceeds 360mg/m2 or its equivalent dose of similar drugs
  • CNS Exclusion - Based on screening brain MRI and clinical assessment; Progressive neurologic impairment or increased intracranial pressure (including nausea, vomiting, blurred vision, headache, epilepsy, etc.); Any intracranial lesion thought to require immediate local therapy; Require antiepileptic treatment (except for these patients with stable seizures require continuous Levetiracetam therapy); Ongoing use of systemic corticosteroids for control of symptoms of brain metastases at a total daily dose of > 2 mg of dexamethasone (or equivalent)
  • There is evidence that other primary tumors are present at the same time

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This will be a phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in patients with HER2-positive advanced solid tumors.

Read full original descriptionShow less

The study will consist of three phases: phase 1a (dose escalation with ZN-A-1041 monotherapy), phase 1b (dose escalation with ZN-A-1041 in combination with Capecitabine and Trastuzumab) and phase 1c (dose expansion with ZN-A-1041 in combination with Capecitabine and Trastuzumab).

The 11 groups in the trial

  • ZN-A-1041 50mgTreatment being tested

    Phase 1a: Subjects will be given ZN-A-1041 orally 50mg Bid, for 21days as one cycle

    Treatment: ZN-A-1041 50mg BID

  • ZN-A-1041 100mgTreatment being tested

    Phase 1a: Subjects will be given ZN-A-1041 orally 100mg Bid, for 21days as one cycle

    Treatment: ZN-A-1041 100mg BID

  • ZN-A-1041 200mgTreatment being tested

    Phase 1a: Subjects will be given ZN-A-1041 orally 200mg Bid, for 21days as one cycle

    Treatment: ZN-A-1041 200mg BID

  • ZN-A-1041 400mgTreatment being tested

    Phase 1a: Subjects will be given ZN-A-1041 orally 400mg Bid, for 21days as one cycle

    Treatment: ZN-A-1041 400mg BID

  • ZN-A-1041 600mgTreatment being tested

    Phase 1a: Subjects will be given ZN-A-1041 orally 600mg Bid, for 21days as one cycle

    Treatment: ZN-A-1041 600mg BID

  • ZN-A-1041 800mgTreatment being tested

    Phase 1a: Subjects will be given ZN-A-1041 orally 800mg Bid, for 21days as one cycle

    Treatment: ZN-A-1041 800mg BID

  • ZN-A-1041 1000mgTreatment being tested

    Phase 1a: Subjects will be given ZN-A-1041 orally 1000mg Bid, for 21days as one cycle

    Treatment: ZN-A-1041 1000mg BID

  • ZN-A-1041 level 1+Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First CycleTreatment being tested

    Phase 1b: ZN-A-1041 Level 1 (The previous dose of MTD) to be used in the combination therapy will be determined based on the MTD identified in the Phase 1a study. Capecitabine will be given at the dose of 1000 mg/m2, BID (2000 mg/m2/day), during the first 2 weeks of the 21-day treatment cycle. Trastuzumab (8 mg/kg in cycle 1 followed by 6 mg/kg beginning in cycle 2, administered as an IV infusion. If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration

  • ZN-A-1041 level 2+Capecitabine 1000 mg/m2+ Trastuzumab 8 mg/kg iv. First CycleTreatment being tested

    Phase 1b: ZN-A-1041 Level 2 ( dose of MTD) to be used in the combination therapy will be determined based on the MTD identified in the Phase 1a study. Capecitabine will be given at the dose of 1000 mg/m2, BID (2000 mg/m2/day), during the first 2 weeks of the 21-day treatment cycle. Trastuzumab (8 mg/kg in cycle 1 followed by 6 mg/kg beginning in cycle 2, administered as an IV infusion. If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration

  • ZN-A-1041 MAD+Capecitabine 1000 mg/m2+Trastuzumab 8 mg/kg iv. First CycleTreatment being tested

    Phase 1b: If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level (MAD) of ZN-A-1041 in Phase 1a will be used in Phase 1b study. If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration

  • ZN-A-1041+Capecitabine+TrastuzumabTreatment being tested

    Phase 1c: The combined dose of ZN-A-1041 is based on the recommended combined dose in the Phase 1b and the possible changes in the dosage form and the results of the food effect study, which will be decided by the sponsor and the investigator after discussion

    Treatment: ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors
Record updated
11 August 2025